The company, helmed by BioNTech alums, is developing therapies aimed at dermatological, respiratory and gut-related ...

By targeting surface markers on cancer cells, engineered synthetic receptors expressed on immune cells can be directed to ...

Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...

AbbVie has entered a partnership and option-to-license agreement with Xilio Therapeutics to develop new tumour-activated, antibody-based immunotherapies. The initiative will include masked T-cell ...

The inhaled monoclonal antibody IN-006 shows promise in COVID-19 treatment, with high airway antibody levels and a favorable safety profile in healthy adults.

Bolt Biotherapeutics, Inc., announced today that the target of their worldwide co-development collaboration with Toray Industries, Inc. is Caprin-1, a novel cancer target discovered by Toray. The ...

Novartis has agreed to acquire Anthos Therapeutics, a Boston-based clinical-stage biopharmaceutical company, for an upfront ...

About Abelacimab Abelacimab is a novel, investigational, highly selective, fully human monoclonal antibody that binds tightly to Factor XI to block its activation and prevent the generation of the ...

From preclinical research to regulatory approval and clinical adoption, diagnostic testing underpins every stage of ADC ...

As part of its continued commitment to developing next-generation cancer therapeutics, Ocean Biomedical is initiating ...

A study from Michigan Medicine researchers has investigated possible genetic factors for drug efficacy for children with Crohn’s disease. In this latest study, HLA DQA1*05 positive children just ...